---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-043166"
form_type: "8-K"
ticker: "NTRB"
cik: "0001676047"
company_name: "NutriBand Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:32:42.294131+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nutriband receives Canadian patent allowance for AVERSA abuse deterrent transdermal technology

## Summary
- Canadian Intellectual Property Office issued Notice of Allowance for patent CA 2937649 covering AVERSA transdermal abuse deterrent technology.
- Patent adds to existing US and Mexico patents, providing IP protection across North America.
- Lead product AVERSA Fentanyl estimated to have peak annual US sales potential of $80M-$200M.
- AVERSA technology aims to deter abuse, diversion, and accidental exposure of opioids like fentanyl in transdermal patches.

## SEC filing metadata
- accession: 0001213900-22-043166
- form_type: 8-K
- ticker: NTRB
- cik: 0001676047
- company_name: NutriBand Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676047/000121390022043166/0001213900-22-043166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676047/000121390022043166/ea163643-8k_nutriband.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-043166
- JSON: https://secwatch.observer/filing/0001213900-22-043166.json
- Plain text: https://secwatch.observer/filing/0001213900-22-043166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.